Changes in Use of Anticoagulation in Patients With Atrial Fibrillation Within a Primary Care Network Associated With the Introduction of Direct Oral Anticoagulants

American Journal of Cardiology

Volumn 120, Issue 5, 2017, Pages 786-791

  Ashburner, Jeffrey M ^a,b   Singer, Daniel E ^a,b   Lubitz, Steven A ^a,b   Borowsky, Leila H ^a   Atlas, Steven J ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APIXABAN; DABIGATRAN; EDOXABAN; RIVAROXABAN; WARFARIN; ANTICOAGULANT AGENT;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; ATRIAL FIBRILLATION; CARDIAC PATIENT; CEREBROVASCULAR ACCIDENT; CHADS2 SCORE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG SUBSTITUTION; DRUG USE; DRUG WITHDRAWAL; ELECTRONIC HEALTH RECORD; FEMALE; GENERAL PRACTITIONER; HIGH RISK PATIENT; HUMAN; LOW RISK PATIENT; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; CLINICAL TRIAL; COMPLICATION; DOSE RESPONSE; INCIDENCE; MASSACHUSETTS; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PRIMARY HEALTH CARE; PROCEDURES; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; STROKE; VERY ELDERLY;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INCIDENCE; MALE; MASSACHUSETTS; PRIMARY HEALTH CARE; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; STROKE;

EID: 85021854869     PISSN: 00029149     EISSN: 18791913     Source Type: Journal    
DOI: 10.1016/j.amjcard.2017.05.055     Document Type: Article

References (30)

1. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 154 (1994), 1449–1457.
2. Singer, D.E., Chang, Y., Fang, M.C., Borowsky, L.H., Pomernacki, N.K., Udaltsova, N., Go, A.S., Should patient characteristics influence target anticoagulation intensity for stroke prevention in nonvalvular atrial fibrillation? The ATRIA study. Circ Cardiovasc Qual Outcomes 2 (2009), 297–304.
3. Connolly, S.J., Ezekowitz, M.D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., Pogue, J., Reilly, P.A., Themeles, E., Varrone, J., Wang, S., Alings, M., Xavier, D., Zhu, J., Diaz, R., Lewis, B.S., Darius, H., Diener, H.C., Joyner, C.D., Wallentin, L., RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361 (2009), 1139–1151.
4. Goette, A., Merino, J.L., Ezekowitz, M.D., Zamoryakhin, D., Melino, M., Jin, J., Mercuri, M.F., Grosso, M.A., Fernandez, V., Al-Saady, N., Pelekh, N., Merkely, B., Zenin, S., Kushnir, M., Spinar, J., Batushkin, V., de Groot, J.R., Lip, G.Y., Investigators E-A. Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial. Lancet 388 (2016), 1995–2003.
5. Granger, C.B., Alexander, J.H., McMurray, J.J., Lopes, R.D., Hylek, E.M., Hanna, M., Al-Khalidi, H.R., Ansell, J., Atar, D., Avezum, A., Bahit, M.C., Diaz, R., Easton, J.D., Ezekowitz, J.A., Flaker, G., Garcia, D., Geraldes, M., Gersh, B.J., Golitsyn, S., Goto, S., Hermosillo, A.G., Hohnloser, S.H., Horowitz, J., Mohan, P., Jansky, P., Lewis, B.S., Lopez-Sendon, J.L., Pais, P., Parkhomenko, A., Verheugt, F.W., Zhu, J., Wallentin, L., ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365 (2011), 981–992.
6. Patel, M.R., Mahaffey, K.W., Garg, J., Pan, G., Singer, D.E., Hacke, W., Breithardt, G., Halperin, J.L., Hankey, G.J., Piccini, J.P., Becker, R.C., Nessel, C.C., Paolini, J.F., Berkowitz, S.D., Fox, K.A., Califf, R.M., Investigators, R.A., Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365 (2011), 883–891.
7. Fang, M.C., Go, A.S., Chang, Y., Borowsky, L.H., Pomernacki, N.K., Udaltsova, N., Singer, D.E., Warfarin discontinuation after starting warfarin for atrial fibrillation. Circ Cardiovasc Qual Outcomes 3 (2010), 624–631.
8. Gomes, T., Mamdani, M.M., Holbrook, A.M., Paterson, J.M., Juurlink, D.N., Persistence with therapy among patients treated with warfarin for atrial fibrillation. Arch Intern Med 172 (2012), 1687–1689.
9. Ogilvie, I.M., Newton, N., Welner, S.A., Cowell, W., Lip, G.Y., Underuse of oral anticoagulants in atrial fibrillation: a systematic review. Am J Med 123 (2010), 638–645 e4.
10. Barnes, G.D., Lucas, E., Alexander, G.C., Goldberger, Z.D., National trends in ambulatory oral anticoagulant use. Am J Med 128 (2015), 1300–1305 e2.
11. Kirchhof, P., Ammentorp, B., Darius, H., De Caterina, R., Le Heuzey, J.Y., Schilling, R.J., Schmitt, J., Zamorano, J.L., Management of atrial fibrillation in seven European countries after the publication of the 2010 ESC Guidelines on atrial fibrillation: primary results of the PREvention oF thromboemolic events—European Registry in Atrial Fibrillation (PREFER in AF). Europace 16 (2014), 6–14.
12. Kirley, K., Qato, D.M., Kornfield, R., Stafford, R.S., Alexander, G.C., National trends in oral anticoagulant use in the United States, 2007 to 2011. Circ Cardiovasc Qual Outcomes 5 (2012), 615–621.
13. Xu, Y., Holbrook, A.M., Simpson, C.S., Dowlatshahi, D., Johnson, A.P., Prescribing patterns of novel oral anticoagulants following regulatory approval for atrial fibrillation in Ontario, Canada: a population-based descriptive analysis. CMAJ Open 1 (2013), E115–E119.
14. Arnsten, J.H., Gelfand, J.M., Singer, D.E., Determinants of compliance with anticoagulation: a case-control study. Am J Med 103 (1997), 11–17.
15. Rodriguez, F., Hong, C., Chang, Y., Oertel, L.B., Singer, D.E., Green, A.R., Lopez, L., Limited English proficient patients and time spent in therapeutic range in a warfarin anticoagulation clinic. J Am Heart Assoc, 2, 2013, e000170.
16. Atlas, S.J., Chang, Y., Lasko, T.A., Chueh, H.C., Grant, R.W., Barry, M.J., Is this “my” patient? Development and validation of a predictive model to link patients to primary care providers. J Gen Intern Med 21 (2006), 973–978.
17. Atlas, S.J., Grant, R.W., Ferris, T.G., Chang, Y., Barry, M.J., Patient-physician connectedness and quality of primary care. Ann Intern Med 150 (2009), 325–335.
18. Murphy, S.N., Morgan, M.M., Barnett, G.O., Chueh, H.C., Optimizing healthcare research data warehouse design through past COSTAR query analysis. Proc AMIA Symp, 1999, 892–896.
19. Lip, G.Y., Nieuwlaat, R., Pisters, R., Lane, D.A., Crijns, H.J., Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation. Chest 137 (2010), 263–272.
20. Grant, R.W., Cagliero, E., Sullivan, C.M., Dubey, A.K., Estey, G.A., Weil, E.M., Gesmundo, J., Nathan, D.M., Singer, D.E., Chueh, H.C., Meigs, J.B., A controlled trial of population management: diabetes mellitus: putting evidence into practice (DM-PEP). Diabetes Care 27 (2004), 2299–2305.
21. Leong, A., Berkowitz, S.A., Triant, V.A., Porneala, B., He, W., Atlas, S.J., Wexler, D.J., Meigs, J.B., Hypoglycemia in diabetes mellitus as a coronary artery disease risk factor in patients at elevated vascular risk. J Clin Endocrinol Metab 101 (2016), 659–668.
22. Ruff, C.T., Giugliano, R.P., Braunwald, E., Hoffman, E.B., Deenadayalu, N., Ezekowitz, M.D., Camm, A.J., Weitz, J.I., Lewis, B.S., Parkhomenko, A., Yamashita, T., Antman, E.M., Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 383 (2014), 955–962.
23. Hsu, J.C., Maddox, T.M., Kennedy, K.F., Katz, D.F., Marzec, L.N., Lubitz, S.A., Gehi, A.K., Turakhia, M.P., Marcus, G.M., Oral anticoagulant therapy prescription in patients with atrial fibrillation across the spectrum of stroke risk: insights from the NCDR PINNACLE registry. JAMA Cardiol 1 (2016), 55–62.
24. Tomlin, A.M., Lloyd, H.S., Tilyard, M.W., Atrial fibrillation in New Zealand primary care: prevalence, risk factors for stroke and the management of thromboembolic risk. Eur J Prev Cardiol 24 (2017), 311–319.
25. Lee, T.M., Ivers, N.M., Bhatia, S., Butt, D.A., Dorian, P., Jaakkimainen, L., Leblanc, K., Legge, D., Morra, D., Valentinis, A., Wing, L., Young, J., Tu, K., Improving stroke prevention therapy for patients with atrial fibrillation in primary care: protocol for a pragmatic, cluster-randomized trial. Implement Sci, 11, 2016, 159.
26. Limone, B.L., Baker, W.L., Kluger, J., Coleman, C.I., Novel anticoagulants for stroke prevention in atrial fibrillation: a systematic review of cost-effectiveness models. PLoS ONE, 8, 2013 e62183.
27. Connors, J.M., Antidote for factor Xa anticoagulants. N Engl J Med 373 (2015), 2471–2472.
28. Savelieva, I., Camm, A.J., Practical considerations for using novel oral anticoagulants in patients with atrial fibrillation. Clin Cardiol 37 (2014), 32–47.
29. Kirchhof, P., Benussi, S., Kotecha, D., Ahlsson, A., Atar, D., Casadei, B., Castella, M., Diener, H.C., Heidbuchel, H., Hendriks, J., Hindricks, G., Manolis, A.S., Oldgren, J., Popescu, B.A., Schotten, U., Van Putte, B., Vardas, P., Agewall, S., Camm, J., Baron Esquivias, G., Budts, W., Carerj, S., Casselman, F., Coca, A., De Caterina, R., Deftereos, S., Dobrev, D., Ferro, J.M., Filippatos, G., Fitzsimons, D., Gorenek, B., Guenoun, M., Hohnloser, S.H., Kolh, P., Lip, G.Y., Manolis, A., McMurray, J., Ponikowski, P., Rosenhek, R., Ruschitzka, F., Savelieva, I., Sharma, S., Suwalski, P., Tamargo, J.L., Taylor, C.J., Van Gelder, I.C., Voors, A.A., Windecker, S., Zamorano, J.L., Zeppenfeld, K., 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 37 (2016), 2893–2962.
30. Dallalzadeh, L.O., Go, A.S., Chang, Y., Borowsky, L.H., Fang, M.C., Singer, D.E., Stability of High-quality warfarin anticoagulation in a community-based atrial fibrillation cohort: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. J Am Heart Assoc, 5, 2016.